Clinical trials
Terminated Lymphoma, Large-Cell, Anaplastic trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
56 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2004 | 3 |
| 2005 | 5 |
| 2006 | 3 |
| 2007 | 4 |
| 2008 | 6 |
| 2009 | 6 |
| 2010 | 6 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 4 |
| 2015 | 2 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2024 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Terminated | 56 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Cancer Institute (NCI) | 11 |
| City of Hope Medical Center | 4 |
| Fred Hutchinson Cancer Center | 4 |
| Barbara Ann Karmanos Cancer Institute | 3 |
| M.D. Anderson Cancer Center | 3 |
| Alliance for Clinical Trials in Oncology | 2 |
| Columbia University | 2 |
| Northside Hospital, Inc. | 2 |
| Seagen Inc. | 2 |
| Seagen, a wholly owned subsidiary of Pfizer | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Lymphoma, Large-Cell, Anaplastic | 56 |
| Lymphoma, Large B-Cell, Diffuse | 42 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 34 |
| Lymphoma, Mantle-Cell | 34 |
| Burkitt Lymphoma | 33 |
| Lymphoma, Follicular | 33 |
| Hodgkin Disease | 32 |
| Immunoblastic Lymphadenopathy | 32 |
| Lymphoma, B-Cell, Marginal Zone | 32 |
| Lymphoma, Non-Hodgkin | 32 |
Trials
Showing 51 to 56 of 56. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.